CLPBF (CLPBF) Stock Price & Analysis
CLPBF (CLPBF) rose 13.05% to USD 65.16 as of June 10, 2026 at 02:23 UTC, according to Nexqual real-time market data.
CLPBF last closed at USD 57.64; the session ranged USD 65.16–65.16 on volume of 3 shares. Market capitalization is $15.10B, with a 52-week range of USD 57.28–100 (PNK). Source: Nexqual, June 10, 2026 at 02:23 UTC.
Key Statistics (as of June 10, 2026 at 02:23 UTC)
| Price | USD 65.16 |
|---|---|
| Change | ▲ 13.05% (up) |
| Previous Close | USD 57.64 |
| Open | USD 65.16 |
| Day Range | USD 65.16 – 65.16 |
| 52-Week Range | USD 57.28 – 100 |
| Volume | 3 shares |
| Market Cap | $15.10B |
| Exchange | PNK |
Technical Analysis (CLPBF)
Nexqual's technical model rates CLPBF "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 02:23 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.04 (oversold) |
| vs SMA50 | Above (USD 63.92) |
| MACD | -1.93 (negative) |
Analyst Ratings (CLPBF)
Wall Street analysts rate CLPBF "None", per Nexqual as of June 10, 2026 at 02:23 UTC.
| Consensus Rating | None |
|---|
Earnings (CLPBF)
| Next Earnings Date | 2026-05-12 |
|---|---|
| Revenue Estimate | $7.25B |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financials & Fundamentals (CLPBF)
| Total Revenue | $28.05B |
|---|---|
| Revenue Growth (YoY) | +2.20% |
| Gross Margin | +67.46% |
| Operating Margin | +25.69% |
| Profit Margin | +7.51% |
| ROE | +14.14% |
| Debt / Equity | 188.65 |
| Current Ratio | 1.75 |
| Total Cash | $1.07B |
| Total Debt | $24.23B |
| Free Cash Flow | $4.20B |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financial Health Score (CLPBF)
Nexqual rates CLPBF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:23 UTC.
| Growth | Mixed — Revenue +3.1% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 67%, operating 26% |
| Balance Sheet | Weak — $1.07B cash vs $24.2B debt |
| Cash Flow | Strong — FCF $4.20B, 15% margin |
| Efficiency | Mixed — ROE 14%, ROA 9.9% |
Ownership (CLPBF)
| Insider Ownership | +29.79% |
|---|---|
| Institutional Ownership | +30.25% |
| Shares Outstanding | 207.37M |
| Float | 143.44M |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Leadership (CLPBF)
CLPBF is led by Gavin Wood (age 54), President & CEO, per Nexqual as of June 10, 2026 at 02:23 UTC.
| President & CEO | Gavin Wood (age 54) |
|---|---|
| Executive VP & CFO | Anders Lonning-Skovgaard (age 53) |
| Executive Vice President of Global Operations | Allan Rasmussen (age 58) |
| Executive Vice President of Chronic Care | Nicolai Buhl Andersen (age 56) |
| Senior Controller & Employees Representative Director | Thomas Barfod (age 55) |
Major Backers & Investors (CLPBF)
Notable institutional backers of CLPBF include MFS SERIES TRUST X-MFS International Intrinsic Value Fund, HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT., JANUS INVESTMENT FUND-Janus Henderson Global Equity Income Fund, according to Nexqual as of June 10, 2026 at 02:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MFS SERIES TRUST X-MFS International Intrinsic Value Fund | 1.06% |
| HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT. | 0.36% |
| JANUS INVESTMENT FUND-Janus Henderson Global Equity Income Fund | 0.26% |
| Baird Funds Inc-Baird Chautauqua International Growth Fund | 0.25% |
| Fidelity | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.53% |
| BlackRock | 0.63% |
| BNY Mellon | 0.46% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLPBY | Coloplast AS | USD 6.06 | ▲ 1% |
| TRUMF | TERUMO CORP | USD 13.6 | ▼ 9.09% |
| SDMHF | Sartorius Stedim Biotech | USD 212.25 | ▲ 0.59% |
| GNMSF | Genmab A/S | USD 249 | ▼ 0.18% |
| CMXHF | CSL Ltd. | USD 66 | ▼ 6.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:23 UTC. This page is informational and not investment advice.